Rates of undetectable HCV-RNA at week 12 ( complete early virologic response [ cEVR ] ; primary end point ) were significantly higher in GT1 ,4 patients receiving Lambda vs. alfa ( 170/304 , 56 % vs. 38/103 , 37 % ) ; with similar cEVR rates for GT2 ,3 ( 80/88 , 91 % vs. 26/30 , 87 % ) .